IRIS
SCARPIGNATO, Carmelo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.004
AS - Asia 12.974
EU - Europa 6.553
SA - Sud America 1.664
AF - Africa 527
Continente sconosciuto - Info sul continente non disponibili 49
OC - Oceania 15
Totale 34.786
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.624
SG - Singapore 5.175
CN - Cina 3.446
VN - Vietnam 1.706
IE - Irlanda 1.494
BR - Brasile 1.307
SE - Svezia 943
DE - Germania 910
HK - Hong Kong 888
FI - Finlandia 862
TR - Turchia 703
IT - Italia 602
NL - Olanda 447
FR - Francia 389
ZA - Sudafrica 376
BD - Bangladesh 362
UA - Ucraina 324
CA - Canada 242
GB - Regno Unito 188
RU - Federazione Russa 162
IN - India 145
AR - Argentina 134
JP - Giappone 74
MX - Messico 71
IQ - Iraq 70
EC - Ecuador 65
EU - Europa 46
CI - Costa d'Avorio 45
PH - Filippine 45
CO - Colombia 42
PK - Pakistan 41
PL - Polonia 39
ID - Indonesia 35
UZ - Uzbekistan 35
VE - Venezuela 33
ES - Italia 31
BE - Belgio 29
KR - Corea 29
MA - Marocco 27
TH - Thailandia 27
PY - Paraguay 26
SA - Arabia Saudita 26
EG - Egitto 25
AT - Austria 24
CL - Cile 21
IR - Iran 21
LT - Lituania 19
TW - Taiwan 17
AE - Emirati Arabi Uniti 16
KE - Kenya 15
CZ - Repubblica Ceca 14
PE - Perù 14
TN - Tunisia 14
JM - Giamaica 13
JO - Giordania 13
RO - Romania 13
MY - Malesia 12
AU - Australia 11
AZ - Azerbaigian 11
CR - Costa Rica 11
KZ - Kazakistan 11
UY - Uruguay 11
BO - Bolivia 8
HU - Ungheria 8
OM - Oman 8
AL - Albania 7
PA - Panama 7
RS - Serbia 7
BG - Bulgaria 6
DZ - Algeria 6
HN - Honduras 6
IL - Israele 6
NP - Nepal 6
AM - Armenia 5
DO - Repubblica Dominicana 5
GT - Guatemala 5
LB - Libano 5
NI - Nicaragua 5
SK - Slovacchia (Repubblica Slovacca) 5
TT - Trinidad e Tobago 5
AF - Afghanistan, Repubblica islamica di 4
BH - Bahrain 4
BY - Bielorussia 4
CG - Congo 4
KG - Kirghizistan 4
LV - Lettonia 4
MD - Moldavia 4
NG - Nigeria 4
PS - Palestinian Territory 4
SY - Repubblica araba siriana 4
GE - Georgia 3
GR - Grecia 3
LU - Lussemburgo 3
QA - Qatar 3
SN - Senegal 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BS - Bahamas 2
CH - Svizzera 2
DK - Danimarca 2
Totale 34.746
Salva come PNG Salva come JPEG
Città #
Singapore 2.288
Dublin 1.491
San Jose 1.460
Chandler 1.347
Ashburn 1.319
Jacksonville 880
Hong Kong 852
Beijing 734
Santa Clara 724
Izmir 617
Dearborn 604
Nanjing 528
Ho Chi Minh City 519
Boardman 475
San Mateo 423
Hanoi 398
Princeton 391
Johannesburg 359
Lauterbourg 330
Dallas 307
Wilmington 241
Los Angeles 227
Parma 177
Shanghai 176
Shenyang 173
Ann Arbor 154
Helsinki 152
Nanchang 152
Toronto 150
Columbus 134
New York 131
Hebei 124
São Paulo 112
Moscow 109
Tianjin 108
Kunming 103
Munich 101
Hefei 94
Jinan 91
Seattle 90
Jiaxing 85
Changsha 84
Buffalo 78
Grafing 73
Norwalk 66
Da Nang 64
Haiphong 62
Frankfurt am Main 54
Tokyo 54
Guangzhou 53
Brooklyn 44
Turku 44
Abidjan 43
Bremen 43
Houston 43
Kocaeli 42
Milan 41
Rio de Janeiro 37
Council Bluffs 34
Des Moines 34
Hangzhou 33
Montreal 33
Woodbridge 33
Chicago 32
Düsseldorf 32
London 32
Can Tho 31
Rome 31
Tashkent 31
Belo Horizonte 30
Boston 30
Hải Dương 30
Orem 30
Warsaw 30
Zhengzhou 29
Biên Hòa 27
The Dalles 27
Atlanta 26
Brussels 26
Chennai 26
Phoenix 26
Baghdad 25
Guarulhos 24
Porto Alegre 24
Guayaquil 23
Mumbai 22
Rockville 22
San Francisco 22
Brasília 21
Stockholm 21
Borås 20
Dhaka 20
Mexico City 20
Nuremberg 19
Quảng Ngãi 18
Denver 17
Fremont 17
Quito 17
Salvador 17
Ankara 16
Totale 20.933
Salva come PNG Salva come JPEG
Nome #
Alginate containing formulations: are they all the same? 179
Myths and misconceptions about chronic constipation 176
[Effect of cimetidine on acute experimental pancreatitis in the rat]. 171
W1079 Curcumin Vs Domperidon in Functional Dyspepsia: Better the Prokinetic or An Agonist of Vanilloid Receptor? 169
Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety 167
Antacids and alginates in the treatment of gastroesophageal reflux disease: how do they work and how much are they clinically useful? 163
Assembled delivery modules for clarithromycin release in Helicobacter Pylori therapy 159
Dysphagia and clinical outcome after laparoscopic Nissen or Rossetti fundoplication: sequential prospective study 157
Gastric function assessed by Gastropanel in very old patients (over 80 years old) and appropriateness of PPIs administration 156
Is the interval between the first and the second H.P. eradication therapy relevant for the success of the cure? A comparison between one week, one month and one year 156
[Protective effect of ranitidine in acute experimental pancreatitis in the rat]. 149
Caustic injury of the upper gastrointestinal tract: A comprehensive review 148
Gastrin 17 in Singling Out Patients with Different Patterns of Refluxate: A Pilot Study Using Impedance-pH as Reference Standard 147
T1082 Eradication Rate of Helicobacter pylori in Immigrant Patients Compared to Italian Patients: Results of a Clinical Trial 146
Corrosive Esophageal Strictures in Children:. Outcomes after Timely or Delayed Dilatation. 145
ASSESSMENT OF SYMPTOMS IN PATIENTS WITH SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE (SUDD) 145
ACID SUPPRESSION THERAPY: WHERE DO WE FROM HERE? 144
M1261 Recurrence of Diverticulitis in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD) Treated Cyclically With Mesalamine: Result of a Follow-up Study 142
Acid suppression in Barrett's esophagus: why and how? 141
P.02.8: Chronic Atrophic Gastritis is Related with an Increased Risk for Cardiovascular Diseases, Assessed by Homocysteine Serum Levels Determination 141
T1979 Pepsinogen II As Marker of Inflammation in H.P Infection and in NSAIDs Damage 141
T1651 The Natural History of Gastric Ulcer: A Twenty-Four Years Clinical-Endoscopical Follow-Up 140
Action of MDL 646, a new synthetic prostaglandin, on gastric acid secretion of some experimental animals. 138
P.1.193: MESALAMINE FOR THE MANAGEMENT OF PATIENTS WITH UNCOMPLICATED DIVERTICULAR DISEASE (SUDD): A 24 MONTHS PROSPECTIVE FOLLOW-UP STUDY 138
P.1.288: PEPSINOGEN I, II, RATIO, AND G-17 IN PATIENTS WITH ESOPHAGITIS AND PATIENTS WITH EXTRA-ESOPHAGEAL MANIFESTATIONS OF GERD 138
PA.28 SERUM PEPSINOGEN I AS NON INVASIVE MARKER OF GASTRIC ACID SECRETION 138
P.29 USEFULNESS OF NON INVASIVE TEST (GASTROPANEL) FOR SCREENING OF ATROPHIC GASTRITIS IN PATIENTS WITH AUTOIMMUNE THYROID DISEASE 138
P.02.18: Non Invasive Diagnosis of Upper Gi Diseases in a Primary Care Setting: A Study on 1,900 Patients 137
Non Invasive Diagnosis of Upper GI Diseases in a Primary Care Setting: A Study on 1,900 Patients 136
Caustic ingestion in children: is endoscopy always indicated? A perspective from a Sierra Leone experience 136
Usefulness of Serum Pepsinogens to Identify Chronic Atrophic Gastritis 135
Corrosive oesophageal strictures in children: outcomes after timely or delayed dilatation 134
M1260 Effect of Cyclically Long-Term Treatment With Mesalamine in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD): A 5 Years Follow-up Study 133
OC3.07.1 CURCUMIN VS DOMPERIDON IN FUNCTIONAL DYSPEPSIA: BETTER THE PROKINETIC OR AN AGONIST OF VANILLOID RECEPTOR? 133
Pepsinogen I, II, Ratio, and G-17 in Patients With Esophagitis and Patients With Extra-Esophageal Manifestations of GERD 133
P.01.7: Efficacy of PPIS and H-2 Blockers Therapy on Acid Suppression Assessed by Gastrin-17 and Pepsinogen I Serum Levels Determination in Gerd Patients 132
PA.6 GASTRIN-17 (G-17): A SEROLOGICAL BIO-MARKER FOR DIAGNOSIS OF GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) 132
Evaluation of clinical outcome after laparoscopic antireflux surgery in clinical practice: still a controversial issue. 131
P.01.14: Overweight and Obesity as Risk Factors for Gerd Outcome: A 10 Years Study on a Gerd Population of 365 Patients 131
EFFECTS OF SOME ANTIULCER DRUGS ON ACUTE EXPERIMENTAL PANCREATITIS IN THE RAT. 130
M1262 Baseline Symptoms in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD) 130
"RESCUE" THERAPIES FOR THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION 129
Antacids and alginate-containing preparations: what is their mechanism of action and their place in the management of GERD? 129
M1141 Diagnostic Accuracy of Serum Pepsinogens and Gastrin to Follow-up Helicobacter pylori Infection: A Pilot Study 129
Quantification of serum levels of pepsinogens and gastrin to assess eradication of Helicobacter pylori 128
FLOTATION OF DOSAGE FORMS AND DEVICES FOR SITE SPECIFIC THERAPY 128
P.05.11 CLINICAL USEFULNESS OF LACTOSE-RESTRICTED DIET IN POSITIVE QUICK LACTASE TEST PATIENTS: PROSPECTIVE 4 MONTHS STUDY 128
ADVANCES IN GI PHARMACOLOGY AND THERAPEUTICS 127
A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation 127
[Cerebral homovanillic acid and audiogenic stress in the rat: effect of Cannabis resin]. 127
Recovery of Gastric Function in Chronic Atrophic Gastritis By Using L-Cysteine: A 3 Years Study 127
P.02.2: Improvement of Symptoms in Patients Affected by Chronic Athrophic Gastritis: A 2 Years Prospective Study by using L-Cysteine (Acetium™) 127
Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats 126
Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers 126
Natural history of gastric ulcer in a 25-years follow-up: role of helicobacter pylori infection and nonsteroidal anti-inflammatory drugs 126
Does the Learning Phase influence the late outcome of patients with gastroesophageal reflux disease after laparoscopic fundoplication? 125
OC.18.1 ARE ALL PATIENTS WITH HISTOLOGICAL DIAGNOSIS OF ATROPHIC GASTRITIS REALLY AT RISK OF DEVELOPING GASTRIC CANCER? ASSESSMENT OF GASTRIC ACID PRODUCTION BY CORRELATION BETWEEN MAXIMAL ACID OUTPUT AND PEPSINOGEN I 124
P.02.7: The Branded Proton Pump Inhibitors (PPIS) Increase Levels of Gastrin 17 (G-17) More than the Generic Ones in Dyspeptic Patients from an Italian Primary Care Population 124
Sa1862 Are All Patients With Histological Diagnosis of Atrophic Gastritis Really At Risk of Developing Gastric Cancer? Assessment of Gastric Acid Production by Correlation Between Maximal Acid Output and Pepsinogen I 123
The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel 122
Antacids in gastroesophageal reflux disease. 122
Distinct receptors mediate gastrin-releasing peptide and neuromedin beta-induced delay of gastric of liquids in rats. 122
P.02.9: Prevalence of Atrophic Gastritis in General Population: A Gastropanel®-Based Study, Compared with Olga Histological Classification 122
Environmental factors (divorce, job changing, night shift change): critical role in IBS outcome. A study on 110 consecutive patients 122
P.02.1: Individual Assessment of Gastric Acid Production by Means of a Non-Invasive Test: Relationship Between Maximal Acid Output and Serum Pepsinogen I Levels in Patients with Different Upper GI Diseases 122
Can gangrenous cholecystitis be prevented?: a plea against a "wait and see" attitude. 121
Antacid protection of the gastric mucosa: an overview. 121
Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy 121
Antidiarroici ed Antispastici 120
Acid-lowering drugs in the treatment of gastroesophageal reflux disease: an overview. 120
OC.07.3 RECOVERY OF GASTRIC FUNCTION AFTER ACETIUM® ADMINISTRATION: A 2 YEAR PROSPECTIVE STUDY IN PATIENTS WITH CHRONIC, ATROPHIC, BODY GASTRITIS 120
In vitro comparison of medicinal products based on alginic acid claimed to protect the esophagus wall and physically prevent acid reflux 119
Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations 119
Sa1988 Recovery of Gastric Function After Helicobacter pylori Eradication and Acetium Administration: A 6 Years Study in Atrophic Gastritis Subjects 118
Action of caerulein on gastric emptying of the conscious rat. 117
Spasmolytic effect of octylonium bromide on gastrointestinal motility in vitro. 117
A simple method for the measurement of human gastric emptying: standardization of operative parameters. 117
Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study 116
Dysphagia aortica: a neglected symptom of aortoesophageal fistula 116
Serum Pepsinogen II as a non-invasive marker for diagnosis of Helicobacter pylori infection: a prospective study in a cohort of dyspeptic patients 116
Monitoring risk factors fot the onset of esophagitis in a long 15-years follow-up 116
NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same? 115
P.01.11: Gastrin 17 in Singling out Patients with Different Pattern of Gastroesophageal Reflux: A Pilot Study using PH-Impedance as Reference Standard 115
P.07.2: Natural History of Symptomatic Uncomplicated Diverticular Disease: A 13-Year Prospective Study 115
Non invasive diagnosis of upper GI disease in a primary care setting: A study on 1900 patients 115
OC.09.2: Appropriateness of PPI Administration in the Elderly: Evaluation of Acid Secretion and Atrophic Gastritis by Means of a Non-Invasive Test 115
Corrosive esophageal injuries in children. A shortlived experience in Sierra Leone 114
P.10 “GASTROPANEL TEST” IN THE CLINICAL OUTCOME OF GERD: PROSPECTIVE SIX MONTHS CLINICAL STUDY 114
How can we measure acid secretion in the single patient? A validated non-invasive surrogate test compared with maximal acid output in 600 people 114
Comparing tapentadol to oxycodone/naloxone combination: building castles in the air. 113
Commentary: towards an effective and safe treatment of small intestine bacterial overgrowth 113
PC.01.2 PREDICTIVE VALUE OF THE “DICA” ENDOSCOPIC CLASSIFICATION ON THE OUTCOME OF THE DIVERTICULAR DISEASE OF THE COLON: AN INTERNATIONAL STUDY 113
[Modalities and diagnostic criteria in esophageal ph monitoring]. 112
P.04.9 DIAGNOSIS OF CHRONIC ATROPHIC GASTRITIS IN PRIMARY CARE SETTING BY MEANS OF GASTROPANEL®: A POPULATION STUDY ON 10,000 CONSECUTIVE PATIENTS 112
P.12.12 INTERMITTENT VERSUS EVERY-DAY MESALAZINE THERAPY IN PREVENTING COMPLICATIONS OF DIVERTICULAR DISEASE OF THE COLON: A LONG-TERM FOLLOW-UP STUDY 111
P.01.5: Serum Pepsinogen II as a Non-Invasive Marker for Diagnosis of Helicobacter Pylori Infection: A Prospective Study in a Cohort of Dyspeptic Patients 111
Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle 110
Italian consensus conference for colonic diverticulosis and diverticular disease 110
Antisecretory and antiulcer effect of the H2-receptor antagonist famotidine in the rat: comparison with ranitidine. 109
P.04.11 A NEW APPROACH TO DETECTION OF NON-RESPONDER PATIENTS IN GERD BY NON-INVASIVE MARKERS 108
Totale 12.980
Salva come PNG Salva come JPEG
Categoria #
all - tutte 131.306
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 131.306
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202123 0 0 0 0 0 0 0 0 0 0 0 23
2021/20221.704 17 4 1 66 61 77 125 308 72 227 201 545
2022/20234.813 671 395 260 341 345 533 20 284 1.779 15 131 39
2023/20241.675 81 177 40 72 177 371 43 117 56 130 178 233
2024/20256.282 87 439 506 250 691 540 109 164 1.056 686 574 1.180
2025/202612.889 1.113 1.252 1.332 1.106 1.910 756 1.617 339 1.726 896 478 364
Totale 34.929